Publication of change in the total number of shares and votes in Diamyd Medical AB

As of April 30, 2015, the share capital in Diamyd Medical AB (publ) is SEK
2,212,988. The total number of votes is 3,044,668 and the total number of shares
is 21,819,422, divided among 958,584 shares of series A (1 vote) and 20,860,838
shares of series B (1/10 vote).

The change is, as announced on March 31, 2015, due to a direct issue of
2,000,000 new series B shares to a group of international institutional
investors. The Board of Diamyd Medical decided on the new issue based on the
authorization given by the Annual General Meeting on November 27, 2014.

About the diabetes vaccine Diamyd®
Type 1 diabetes is a devastating disease which requires daily treatment with
insulin to sustain life. The importance of finding a cure should not be
underestimated. Diamyd® is considered to be the world’s furthest developed
Antigen Based Therapy (ABT) for treating the disease. Diamyd® has been used in
clinical studies with more than 1,000 patients and has shown a good safety
profile. In a European Phase III study Diamyd® showed good clinical effect in
several subgroups, and a limited overall 16% efficacy (p=0.10) in preserving
endogenous insulin secretion. To enhance the overall effect, combination
treatments with Diamyd® and other approved agents are being pursued. Diamyd® is
easy to administer in any clinical setting. The potential annual market is
estimated to several billion dollars.

About Diamyd Medical
Diamyd Medical is dedicated to working toward a cure for type 1 diabetes and
LADA. The Company’s projects include development of combination regimens with
the GAD-based diabetes vaccine Diamyd® for arresting the destruction of insulin
-producing beta cells. The Company exclusively licenses UCLA-rights to GAD65,
the active ingredient in the vaccine, for which the last patent expires in 2032.
Additionally, the Company exclusively licenses UCLA patents for using GABA for
the treatment of diabetes and other inflammation-related conditions.

Diamyd Medical is one of the major shareholders in the stem cell company
Cellaviva AB, which is establishing a Swedish commercial bank for private family
saving of stem cells in umbilical cord blood and other sources of stem cells.
Stem cells can be expected to be used in Personalized Regenerative Medicine
(PRM), for example, to restore beta cell mass in diabetes patients where
autoimmunity has been arrested.

Remium Nordic AB is the Company’s Certified Adviser.
For further information, please contact:
Anders Essen-Möller, President and CEO
Phone: +46 70 55 10 679. E-mail: anders.essen-moller@diamyd.com
Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8
661 63 68
E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com.